fda tirzepatide shortage update The Outsourcing Facilities Association (OFA) is suing the after the agency removed (Zepbound, Mounjaro) from the federal drug list without proper notice. The lawsuit claims that the FDA failed Patients can't wait and neither
Description
Other Potential Risks Tirzepatide can, in some cases, cause low blood sugar (hypoglycemia)
Turcot, V
Tirzepatide activates both GIP and GLP-1, which is why it is called a dual agonist
These metabolic benefits are one reason Found's clinicians consider tirzepatide for people whose weight is affecting other areas of their health
Related article: How to Inject Mounjaro and Use the Pen Injector Correctly
Yes, while Tirzepatide was originally FDA-approved for the treatment of type 2 diabetes, this medication is now available specifically for weight loss
